BridgeMD
New treatment option for Cancer
Official title Re-Engaging AYA Survivors in Cancer-Related Healthcare
ClinicalTrials.gov ID: NCT07138040
What this study is testing
- What it's testing
- The goal of this clinical trial is to test the efficacy (how well they work) of different digital interventions that deliver information to adolescent and young adult (AYA) survivors of childhood cancer to promote re-engagement in cancer-related long-term follow-up care (LTFU). The main aims are: To test the efficacy of adaptive interventions (AIs) that begin with low touch intervention (LTI) as compared to written information (WI) on attending an appointment, and self-reported self-management among AYA.
- Time commitment: about 4 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 15 to 29
You may be able to join if
- for AYA
- 15-29 years old
- History of a childhood cancer diagnosis, diagnosed prior to age 22
- Has not had a cancer-related follow-up visit in at least 15 months (or is 3 months past recommended follow-up)
- U.S. resident (not international patient)
You likely can't join if
- for AYA
- Cognitive impairment limiting participation
- Received surgery only treatment
- Transferred to primary care
- Currently living with cancer diagnosis (either new, metastatic, recurrence, or relapse)
- Absence of documentation of treatment history
See the full eligibility criteria
- for AYA
- 15-29 years old
- History of a childhood cancer diagnosis, diagnosed prior to age 22
- Has not had a cancer-related follow-up visit in at least 15 months (or is 3 months past recommended follow-up)
- U.S. resident (not international patient)
- Has previously attended a cancer-related appointment at Children's Hospital of Philadelphia, or Nationwide Children's Hospital or Penn
- At least 2 years from end of treatment and 5 years from diagnosis
- English proficient
- For AYA under age 18, must have a caregiver to provide informed consent
- for AYA
- Cognitive impairment limiting participation
- Received surgery only treatment
- Transferred to primary care
- Currently living with cancer diagnosis (either new, metastatic, recurrence, or relapse)
- Absence of documentation of treatment history
- Absence of inclusion criteria above Inclusion Criteria for Support Person of AYA
- Primary caregiver or other support person (e.g. partner, sibling, other caregiver)
- At least 18 years old
- U.S. resident
- English proficient Exclusion Criteria for Support Person of AYA
- No involvement in the AYA's healthcare
- AYA Decline support person's participation
- Absence of inclusion criteria above
The study team makes the final eligibility decision.
Where it's taking place
- Columbus, Ohio, United States
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 4 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 15 years to 29 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Columbus, Ohio, United States; Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.